Verve Therapeutics’ $306 Million IPO

Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on the deal.

Verve Therapeutics (Nasdaq: VERV), a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, announced the closing of its initial public offering of 16,141,157 shares of its common stock, which includes 2,105,368 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $19.00 per share. Including the option exercise, the aggregate gross proceeds to Verve Therapeutics from the offering were approximately $306.7 million, before deducting the underwriting discounts and commissions and offering expenses.

J.P. Morgan, Jefferies, Guggenheim Securities and William Blair acted as joint book-running managers for the offering.

The team that advised Verve on IP matters related to the IPO includes Vern Norviel (Picture), Clark Lin, Ying Chen, Angel Wang, and Moonkyoung Um.

The WilmerHale team advising Verve Therapeutics was led by Lia Der Marderosian, Craig Hilts and Ciara Baker, and included Timothy Kulis, Erin Garrity, Chris Shin and Alex Bloom.

Involved fees earner: Ciara Baker – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Alexander Bloom – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Lia Der Marderosian – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Erin Garrity – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Craig Hilts – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Timothy Kulis – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Christopher Shin – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Ying Chen – Wilson Sonsini Goodrich & Rosati; Clark Lin – Wilson Sonsini Goodrich & Rosati; Vern Norviel – Wilson Sonsini Goodrich & Rosati; Moonkyoung Um – Wilson Sonsini Goodrich & Rosati; Angel Wang – Wilson Sonsini Goodrich & Rosati;

Law Firms: WilmerHaleWilmer Cutler Pickering Hale and Dorr; Wilson Sonsini Goodrich & Rosati;

Clients: Verve Therapeutics;

Author: Martina Bellini